Abstract:Nucleus accumbens-1 (NAC1), a nuclear factor belonging to the BTB/POZ gene family, is known to have important roles in proliferation and growth of tumor cells and in chemotherapy resistance. Yet, the mechanisms underlying how NAC1 contributes to drug resistance remain largely unclear. We report here that autophagy was involved in NAC1-mediated resistance to cisplatin, a commonly used chemotherapeutic drug in the treatment of ovarian cancer. We found that treatment with cisplatin caused an activation of autophagy in ovarian cancer cell lines, A2780, OVCAR3 and SKOV3. We further demonstrated that knockdown of NAC1 by RNA interference or inactivation of NAC1 by inducing the expression of a NAC1 deletion mutant that contains only the BTB/POZ domain significantly inhibited the cisplatin-induced autophagy, resulting in increased cisplatin cytotoxicity. Moreover, inhibition of autophagy and sensitization to cisplatin by NAC1 knockdown or inactivation were accompanied by induction of apoptosis. To confirm that the sensitizing effect of NAC1 inhibition on the cytotoxicity of cisplatin was attributed to suppression of autophagy, we assessed the effects of the autophagy inhibitors 3-methyladenosine and chloroquine, and small interfering RNAs (siRNAs) targeting beclin 1 or Atg5 on the cytotoxicity of cisplatin. Treatment with 3-methyladenosine, chloroquine or beclin 1 and Atg5-targeted siRNA also enhanced the sensitivity of SKOV3, A2780 and OVCAR3 cells to cisplatin, indicating that suppression of autophagy indeed renders tumor cells more sensitive to cisplatin. Regulation of autophagy by NAC1 was mediated by the high-mobility group box 1 (HMGB1), as the functional status of NAC1 was associated with the expression, translocation and release of HMGB1. The results of our study not only revealed a new mechanism determining cisplatin sensitivity but also identified NAC1 as a novel regulator of autophagy. Thus, the NAC1-mediated autophagy may be exploited as a new target for enhancing the efficacy of cisplatin against ovarian cancer and other types of malignancies.

Identification of a Small-Molecule Compound That Inhibits Homodimerization of Oncogenic NAC1 Protein and Sensitizes Cancer Cells to Anticancer Agents

Effective Targeting of NAC1 Dimerization by a Small-Molecule Inhibitor and Application to Cancer Combination Therapy

Co-Targeting Nucleus Accumbens Associate 1 and NF-κB Signaling Synergistically Inhibits Melanoma Growth

Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion

Nucleus Accumbens-Associated Protein-1 Promotes Glycolysis and Survival of Hypoxic Tumor Cells Via the HDAC4-HIF-1α Axis

Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol.

Combined inhibition of JAK1/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells

Targeting of tumoral NAC1 mitigates myeloid-derived suppressor cell-mediated immunosuppression and potentiates anti-PD-1 therapy in ovarian cancer

Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability

NAC1 Attenuates BCL6 Negative Autoregulation and Functions As a BCL6 Coactivator of FOXQ1 Transcription in Cancer Cells.

Systemic Delivery of NAC-1 Sirna by Neuropilin-Targeted Polymersomes Sensitizes Antiangiogenic Therapy of Metastatic Triple-Negative Breast Cancer.

NAC1 Modulates Sensitivity of Ovarian Cancer Cells to Cisplatin by Altering the HMGB1-mediated Autophagic Response

Inhibition of Ciap1 As a Strategy for Targeting C-Myc-driven Oncogenic Activity.

NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer

Small molecules targeting Pin1 as potent anticancer drugs

Mechanistic Insights of NAC1 Nuclear Export and Its Role in Ovarian Cancer Resistance to Docetaxel

A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells

Targeting oncogenic transcriptional corepressor Nac1 POZ domain with conformationally constrained peptides by cyclization and stapling.

Covalent inhibition of NSD1 histone methyltransferase

A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresistance in Notch1-hyperactivated pancreatic cancer

A Small Molecule Inhibitor of the UBE2F-CRL5 Axis Induces Apoptosis and Radiosensitization in Lung Cancer